Evidence map›Paper›PMID 29438824›Full record

ArticleBone2018

Low bone toughness in the TallyHO model of juvenile type 2 diabetes does not worsen with age.

Amy Creecy, Sasidhar Uppuganti, Mustafa Unal, R Clay Bunn, Paul Voziyan, Jeffry S Nyman

Abstract read
In one paragraph

Article in Bone, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Identifying Bone Matrix Impairments in a Mouse Model of Neurofibromatosis Type 1 (NF1) by Clinically Translatable Techniques.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022
    Article
  10. The relative contribution of bone microarchitecture and matrix composition to implant fixation strength in rats.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Effects of Diabetes on Bone Material Properties.Current osteoporosis reports · 2019
    Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Amy CreecyDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN 37232, United States; Department of Orthopaedic Surgery & Rehabilitation, Vanderbilt University Medical Center, Nashville, TN 37232, United States; Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN 37232, United States.
Sasidhar UppugantiDepartment of Orthopaedic Surgery & Rehabilitation, Vanderbilt University Medical Center, Nashville, TN 37232, United States; Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN 37232, United States.
Mustafa UnalDepartment of Orthopaedic Surgery & Rehabilitation, Vanderbilt University Medical Center, Nashville, TN 37232, United States; Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN 37232, United States.
R Clay BunnUniversity of Kentucky Barnstable Brown Diabetes Center, Lexington, KY 40536, United States; Department of Pediatrics, University of Kentucky College of Medicine, Lexington, KY 40536, United States.
Paul VoziyanDepartment of Medicine, Division of Nephrology, Vanderbilt University Medical Center, Nashville, TN 37232, United States; Center for Matrix Biology, Vanderbilt University Medical Center, Nashville, TN 37232, United States.
Jeffry S NymanDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN 37232, United States; Department of Orthopaedic Surgery & Rehabilitation, Vanderbilt University Medical Center, Nashville, TN 37232, United States; Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN 37232, United States; Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN 37212, United States. Electronic address: jeffry.s.nyman@vanderbilt.edu.
Vanderbilt University Medical Center · USVanderbilt University · USUniversity of Kentucky · US

Funding

Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALVIN C POWERS · 2012 to 2026
$29.3M
TRANSGENIC MOUSE/ ES CELL SHARES RESOURCESP60DK020593 · NIDDK · VANDERBILT UNIVERSITY · PI POWERS, ALVIN C · 1986 to 2011
$28.1M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
Vanderbilt Mouse Metabolic Phenotyping CenterU2CDK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2016 to 2021
$6.3M
Integrated Training in Engineering and DiabetesT32DK101003 · NIDDK · VANDERBILT UNIVERSITY · PI Jamey D. Young · 2014 to 2026
$3.9M
Effects of Sodium-dependent Glucose Co-transporter 2 Inhibition on Bone.R21AR070620 · NIAMS · UNIVERSITY OF KENTUCKY · PI NYMAN, JEFFRY STEPHEN, THRAILKILL, KATHRYN M · 2016 to 2017
$387k
The Role of Tissue Matrix in the Fracture Resistance of Diabetic BoneR21AR067871 · NIAMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI NYMAN, JEFFRY STEPHEN · 2016 to 2017
$382k
BLRD VA I01 BX004297NIAMS NIH HHS R21 AR067871NIAMS NIH HHS R21 AR070620NIDDK NIH HHS P30 DK020593NIDDK NIH HHS T32 DK101003NIDDK NIH HHS U24 DK059637NIDDK NIH HHS U2C DK059637
6 · The paper itself

Abstract

Fracture risk increases as type 2 diabetes (T2D) progresses. With the rising incidence of T2D, in particular early-onset T2D, a representative pre-clinical model is needed to study mechanisms for treating or preventing diabetic bone disease. Towards that goal, we hypothesized that fracture resistance of bone from diabetic TallyHO mice decreases as the duration of diabetes increases. Femurs and lumbar vertebrae were harvested from male, TallyHO mice and male, non-diabetic SWR/J mice at 16weeks (n≥12 per strain) and 34weeks (n≥13 per strain) of age. As is characteristic of this model of juvenile T2D, the TallyHO mice were obese and hyperglycemic at an early age (5weeks and 10weeks of age, respectively). The femur mid-shaft of TallyHO mice had higher tissue mineral density and larger cortical area, as determined by micro-computed tomography, compared to the femur mid-shaft of SWR/J mice, irrespective of age. As such, the diabetic rodent bone was structurally stronger than the non-diabetic rodent bone, but the higher peak force endured by the diaphysis during three-point (3pt) bending was not independent of the difference in body weight. Upon accounting for the structure of the femur diaphysis, the estimated toughness at 16weeks and 34weeks was lower for the diabetic mice than for non-diabetic controls, but neither toughness nor estimated material strength and resistance to crack growth (3pt bending of contralateral notched femur) decreased as the duration of hyperglycemia increased. With respect to trabecular bone, there were no differences in the compressive strength of the L6 vertebral strength between diabetic and non-diabetic mice at both ages despite a lower trabecular bone volume for the TallyHO than for the SWR/J mice at 34weeks. Amide I sub-peak ratios as determined by Raman Spectroscopy analysis of the femur diaphysis suggested a difference in collagen structure between diabetic and non-diabetic mice, although there was not a significant difference in matrix pentosidine between the groups. Overall, the fracture resistance of bone in the TallyHO model of T2D did not progressively decrease with increasing duration of hyperglycemia. However, given the variability in hyperglycemia in this model, there were correlations between blood glucose levels and certain structural properties including peak force.

Indexed as

AgingAnimalsArginineBone DensityChromatography, High Pressure LiquidDiabetes Mellitus, Type 2FemurFractures, BoneLysineMaleMiceSpectrum Analysis, RamanX-Ray MicrotomographyArginineLysinepentosidineBone qualityFracture riskMechanical propertiesMicro-computed tomographyPentosidineRaman spectroscopyType 2 diabetes

Identifiers

PMID29438824
PMCPMC5878744
OpenAlexW2791897953

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.